{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:56:27Z","timestamp":1792130187453,"version":"4.4.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.2169\/internalmedicine.6292-20","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T22:06:14Z","timestamp":1612735574000},"page":"29-35","source":"Crossref","is-referenced-by-count":35,"title":["Adverse Effects of Kampo Medicines"],"prefix":"10.2169","volume":"61","author":[{"given":"Yutaka","family":"Shimada","sequence":"first","affiliation":[{"name":"Department of Japanese Oriental Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Japan Kampo Medicines Manufacturers Association. [Kampo future vision 2040] [Internet]. 2018 Jul 20 [cited 2020 Aug 31]. Available from: https:\/\/www.nikkankyo.org\/action\/pdf\/vision2040.pdf (in Japanese)"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shimada Y, Fujimoto M, Nogami T, Watari H. Adverse events associated with ethical Kampo formulations: analysis of the domestic adverse-event data reports of the Ministry of Health, Labor, and Welfare in Japan. Evid Based Complement Alternat Med 1643804, 2019.","DOI":"10.1155\/2019\/1643804"},{"key":"3","unstructured":"3. Japan Kampo Medicines Manufacturers Association. [Production dynamics of Kampo products] [Internet]. 2019 Sep 20 [cited 2020 Aug 31]. Available from: https:\/\/www.nikkankyo.org\/serv\/movement\/h30\/all.pdf (in Japanese)"},{"key":"4","unstructured":"4. Japan Kampo Medicines Manufacturers Association. [Actual condition survey of Kampo prescriptions] [Internet]. 2011 Oct 18 [cited 2020 Aug 31]. Available from: https:\/\/www.nikkankyo.org\/serv\/pdf\/jittaichousa2011.pdf (in Japanese)"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Terada M, Kitazawa H, Kawakami J, Adachi I. Pharmacoepidemiology of interstitial pneumonia and liver dysfunction associated with Kampo medicine. Iryo Yakugaku (Jpn J Pharmal Health Care Sci) 28: 425-434, 2002 (in Japanese, Abstract in English).","DOI":"10.5649\/jjphcs.28.425"},{"key":"6","unstructured":"6. Tsukiyama K, Tasaka Y, Nakajima M, et al. A case of pneumonitis due to sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi (Jpn J Thorac Dis) 27: 1556-1561, 1989 (in Japanese, Abstract in English)."},{"key":"7","unstructured":"7. Serious adverse effect &quot;interstitial pneumonia&quot; caused by administration of shosaikoto: from Pharmaceuticals Safety Information No. 137 (May 1996). Nihon Toyo Igaku Zasshi (Jpn J Orient Med) 47: 81-83, 1996 (in Japanese)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Enomoto Y, Nakamura Y, Enomoto N, Fujisawa T, Inui N, Suda T. Japanese herbal medicine-induced pneumonitis: a review of 73 patients. Respir Investig 55: 138-144, 2017.","DOI":"10.1016\/j.resinv.2016.11.007"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51: 260-277, 2013.","DOI":"10.1016\/j.resinv.2013.09.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nogami T, Fujimoto M, Shimada Y, et al. Incidence of kampo medicine-induced interstitial pneumonia: 10 year retrospective study at a university hospital kampo medicine department. Tradit Kampo Med 6: 26-31, 2019.","DOI":"10.1002\/tkm2.1211"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 39: 427-431, 2009.","DOI":"10.1111\/j.1872-034X.2008.00486.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Itoh T, Sugao M, Chijiwa T, et al. Clinical characteristics of side effects induced by administration of Glycyrrhizae Radix and Scutellaria Radix under the therapy based on kampo diagnosis in our hospital. Nihon Toyo Igaku Zasshi (Kampo Med) 61: 299-307, 2010 (in Japanese, Abstract in English).","DOI":"10.3937\/kampomed.61.299"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Makino T. 3-Monoglucuronyl glycyrrhretinic acid is a possible marker compound related to licorice-induced pseudoaldosteronism. Biol Pharm Bull 37: 898-902, 2014.","DOI":"10.1248\/bpb.b13-00997"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takahashi K, Yoshino T, Maki Y, et al. Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study. Arch Toxicol 93: 3111-3119, 2019.","DOI":"10.1007\/s00204-019-02588-2"},{"key":"15","unstructured":"15. Ohtsu K, Matsui T, Nishimura T, et al. Association between mesenteric phlebosclerosis and Chinese herbal medicine intake. Nihon Shokakibyo Gakkai Zasshi (J Jpn Soc Gastroenterol) 111: 61-68, 2014 (in Japanese, Abstract in English)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nagata Y, Watanabe T, Nagasaka K, et al. Total dosage of gardenia fruit used by patients with mesenteric phlebosclerosis. BMC Complement Altern Med 16: 207, 2016.","DOI":"10.1186\/s12906-016-1182-1"},{"key":"17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0140-6736(93)92984-2","volume":"341","author":"JL Vanherweghem","year":"1993","unstructured":"17. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387-391, 1993.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74: 158-169, 2008.","DOI":"10.1038\/ki.2008.129"},{"key":"19","unstructured":"19. Pharmaceuticals and Medical Devices Safety Information No. 200 April 2004 [Internet]. [cited 2020 Nov 18]. Available from: https:\/\/www.pmda.go.jp\/files\/000153652.pdf"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chino A, Tsuji M, Yagi A, Terasawa K. Polypharmacy caused by Kampo prescriptions. Nihon Toyo Igaku Zasshi (Kampo Med) 70: 72-76, 2019 (in Japanese, Abstract in English).","DOI":"10.3937\/kampomed.70.72"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shimada Y, Fujimoto M, Nogami T, et al. Recurrent drug-induced liver injury caused by the incidental readministration of a Kampo formula containing Scutellariae Radix. Intern Med 57: 1733-1740, 2018.","DOI":"10.2169\/internalmedicine.0275-17"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/1\/61_6292-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T03:17:45Z","timestamp":1641007065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/1\/61_6292-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6292-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]},"article-number":"6292-20"}}